‘Game changer’ for opioid dependence

Buvidal (buprenorphine prolonged release solution) is now available allowing weekly and monthly treatment of opioid dependence within a medical, social and psychological framework in patients aged 16 years or older.

Manufacturer Camurus says that Buvidal uses its proprietary FluidCrystal technology. Once injected, the lipid-based solution transforms into a gel-like depot that slowly biodegrades, releasing buprenorphine, which reduces withdrawal, craving and use of illicit opioids.

“New forms of buprenorphine, given as weekly or monthly subcutaneous depot injections could become a game changer in opioid dependence treatment by improving adherence and reducing the burden, stigma and risks of daily treatment,” says Professor Sir John Strang of the National Addiction Centre, King’s College, London.

Recommended

Oral impact

Welsh pharmacy flu jab success




This website is for healthcare professionals, people who work in pharmacy and pharmacy students. By clicking into any content, you confirm this describes you and that you agree to Pharmacy Magazine's Terms of Use and Privacy Policy.

We use essential, performance, functional and advertising cookies to give you a better web experience. Find out how to manage these cookies here. We also use Interest Based Advertising Cookies to display relevant advertisements on this and other websites based on your viewing behaviour. By clicking "Accept" you agree to the use of these Cookies and our Cookie Policy.